KAM
PCRX icon

Kazazian Asset Management’s Pacira BioSciences PCRX Stock Holding History

Kazazian Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,247
Closed -$197K – 84
2017
Q3 		$197K Buy
+5,247
New +$211K 0.24% 62

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Kazazian Asset Management's PCRX Position: Q4 2017 in Review

Kazazian Asset Management sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 5,247 shares — an estimated $197K sold.

Kazazian Asset Management first reported a position in PCRX in Q3 2017 and held it in 1 quarter. The position peaked at $197K in Q3 2017. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Kazazian Asset Management reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Kazazian Asset Management sold 5,247 Pacira BioSciences shares in Q4 2017, an estimated $197K.
  • Kazazian Asset Management first reported a position in Pacira BioSciences in Q3 2017 and held it in 1 quarter.
  • Kazazian Asset Management's Pacira BioSciences position peaked at $197K in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Kazazian Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.